Next Phase Newsletter

A large pharmaceutical company headquartered in China’s main business covers chemical and biological medicines, pharmaceutical packaging, and trading. Its investment subsidiary has 200 million RMB assets under management, and is looking for investment and in-licensing opportunities in novel drug research and development. The firm also invests in funds. The firm’s allocation size is decided case by case.

The firm is most interested in companies developing novel drugs in Biologics, Cell therapy, Gene therapy, Repurposed drugs, and Biosimilar. The firm is interested in distribution rights. In terms of stage of development, companies that are at or before the NDA stage are preferred (Pre-clinical, Phase I, Phase II, Phase III, NDA).

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An international family of venture capital funds that invests in early-stage, high-growth life science and health technology companies in the US, UK, and Europe. The firm invests via a two fund structure, and is currently investing out of one Europe-based fund, and is actively raising a USA fund to focus on investing in USA-based companies. The EU fund primarily provides Series A financing in the range of £2-5M. The EU fund is actively seeking new investment opportunities in the UK and Europe. In the USA, Epidarex is interested in Seed and Series A opportunities.

The firm is currently seeking to invest in novel early stage biotech therapeutic and diagnostic, medical devices and pharmaceuticals. The firm is opportunistic in terms of subsectors and indications. The firm is also interested in other areas such as personalized medicine, healthcare IT and services. For therapeutics, the firm focuses on products in pre-clinical and early clinical and will consider orphan indications.

The firm requests a board seat in each portfolio company. The firm invests in management teams who are highly driven and tenacious problem solvers.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in the USA is actively investing in Seed to Series A rounds. In addition to providing equity capital, the firm will also assist companies with intellectual property. The firm is open to opportunities in North America (USA and Canada).

The firm is interested in early-stage medical technology, diagnostics, and digital health/wellness companies and is open to medical devices of all regulatory pathways including 510k and PMA. The firm strongly prefers products that have received FDA clearance but is open to working with pre-FDA products. The firm will generally not pursue opportunities in biopharma therapeutics.

The firm to work with privately owned companies that are backed by an experienced management team. The firm likes to form syndicates and prefers co-investing in financing rounds, but the firm can lead rounds as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A wholly owned subsidiary of a large health system engages in strategic investments across a wide variety of sectors to benefit the health system. The firm invests at a set pace with ~2 surgery centers being invested in per year and are currently looking to diversify their portfolio. The firm tends to invest in seed and pre-revenue rounds as their allocation size is on the smaller side, but is interested in revenue generating opportunities with smaller rounds. The firm is currently in the process of diversifying their portfolio and prefers investing in companies that are related to the health system in some way, companies that have done clinical studies within the health system, etc.

The firm is particularly interested in technologies that can help them increase the quality of care, decrease the cost of care, and increase the access of services to populations which have been historically denied. Beyond that though, the firm is rather opportunistic within the digital health, medical devices, healthcare services, and care delivery spaces and currently has no specific focus.

The firm requires that companies have some sort of relationship with the firm or have the endorsement of the senior management of the health system.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A PE firm based in China manages 2 active funds that focus on investments in the life science space. Their RMB fund invests $5-40 M in companies based in China, and their USD invests $5-10 M in companies of all parts of the world, with a focus in USA and China. With these funds, the firm will make investments in companies that have market opportunities in China. The firm will provide companies with resources and expertise for competitive market entry and will assist pre-market products with commercialization.

The firm is opportunistic and is open to all life science sectors in all indications, including therapeutics, medical technology, diagnostics, and digital health. In therapeutics, the firm will consider products that are in Phase II clinical trials and beyond, but may consider companies with pre-clinical or early clinical assets if they demonstrate high potential. In the medical technology sector, the firm will support devices of all regulatory pathways and will also assist with CFDA regulatory filing and approval. These devices are expected to be undergoing pivotal trials at the earliest, and should be close to commercialization.

The firm will invest only in companies that are looking to enter the market in China, and is willing to both lead and co-invest. The companies will ideally have an IPO or trade sale runway of 6 to 24 months. Companies should be backed by an experienced management team but for companies based in China, the firm can assist with the assembly of a complete management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the USA makes initial investments from $5-$15M with $35M over the lifetime of the company. The firm invests globally and has particular experience with partners located in the USA and Western Europe.

The firm seeks early-stage nanotechnology and stem cell research, particularly in cancer, therapeutic and regenerative medicine. The firm is primarily interested in clinical stage Ph I/II technology. The firm focuses their expertise in regenerative and therapeutic medicine, with a focus on stem cell biology, immunology, oncology, and nanotechnology to identify opportunities in the treatment of a broad range of diseases. Specific to oncology, the firm is interested in novel cancer therapies, immunotherapy, new chemotherapies, targeted therapy, management of adverse consequences, and quality of life improvement.

The firm requires management teams with experience in the field. The firm seeks board representation post-investment and remains actively supportive with portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in the USA and Western Europe currently manages two funds, and typically makes equity investment into early-stage life science companies. The typical investment size ranges from €0.5million-€8million ($0.7million-$10million). The second fund looks to make 10 to 15 investments. The firm generally invests in companies based in the US and Europe.

The firm is currently looking for new investment opportunities in the life science space. The firm focuses on Therapeutics, Diagnostics and Medical Devices sectors. The firm is very opportunistic in terms of subsectors and indications, and it is most interested in companies in pre-clinical and clinical stages. In the past, the firm was active in therapeutics companies targeting drug delivery and gene therapy. The firm was also active in device companies developing single use cardiovascular devices and implantable devices.

The firm primarily invests in private companies with experienced management teams, but it will also consider public companies, depending on the opportunity. The firm seeks to take a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.